ISPOR 14th AnnuAl EuROPEAn COngRESS

5-8 nOvEmbER 2011hOtEl AudItóRIum mAdRId

mAdRId, SPAIn

international society for pharmacoeconomics and outcomes research

Rational Health Care Decision Making in Challenging Economic Times

fOR mORE InfO: www.ISPOR.ORg

PROgRAmEarly rEgistration DEaDlinE: 20 sEptEmbEr 2011

KEY InfORmAtIOn

OVER 1500PRESENTATIONS22% INcREASE IN AbSTRAcTS SubmITTEd!

CongrEss program CommittEE

PROGRAM COMMITTEE CHAIRXavier Badia, phd, md, mph, Global Leader, Observational COE & Senior Principal, HEOR, IMS Health, Barcelona, Spain

RESEARCH REVIEW COMMITTEE CO-CHAIRSJan J.V. Busschbach, phd, Interim Director, Department of Medical Psychology & Psychotherapy, Erasmus MC, Rotterdam, The Netherlandsdominik Golicki, md, phd, ma, Partner, HealthQuest sp z o.o., Warsaw, Poland michael schlander, phd, md, mBa, Chairman & Scientific Director, Institute for Innovation & Valuation in Health Care (InnoVal), Wiesbaden, Germanyerkki soini, msc, rn, Chief Executive Officer, ESiOR Ltd., Kuopio, Finland

WORKSHOP REVIEW COMMITTEE CO-CHAIRSfernando antoñanzas, ma, phd, Economist, Department of Economics, University of La Rioja, Logrono, Spain nancy J. devlin, phd, Director of Research, Office of Health Economics, London, UK

ISSUE PANEL REVIEW COMMITTEE CO-CHAIRSpeter hertzman, phd, Executive Director, HEOR, BMS Europe, Rueil Malmaison, FranceJacco Keja, phd, Regional Leader, EMEA, HEOR, IMS Health, London, UK and Lecturer in Life Sciences Pricing and Management, Institute for Health Policy and Management, Erasmus University, Rotterdam, The Netherlands

DECISION-MAKER CASE STUDY REVIEW COMMITTEE CHAIRantoni Gilabert perramon, phd, Managing Director of Pharmaceutical Care and Complementary Benefits, Catalan Health Service, Department of Health and Social Security, Government of Catalonia, Barcelona, Spain

CongrEss promotional opportUntiEseXhiBit: Register now! Over 2900 attendees in 2010!adVertise: Advertise in the Program and Schedule of Events! sponsor: Give your company increased visibility and prominence!ADVERTISING DEADLINE: 16 September 2011

rEsEarCH postEr prEsEntationsPOSTER SESSION I: SUNDAY, 6 NOVEMBERSet-Up: 11:30-12:00Poster Display Hours: 12:00-20:00Poster Author Discussion Hour: 18:15-19:15Dismantle: 20:00-20:30

POSTER SESSION II: MONDAY, 7 NOVEMBERSet-Up: 7:30-8:00Poster Display Hours: 8:00-19:30Poster Author Discussion Hour: 17:30-18:30Dismantle: 19:30-20:00

POSTER SESSION III: TUESDAY, 8 NOVEMBERSet-Up: 7:30-8:00Poster Display Hours: 8:00-16:00Poster Author Discussion Hour: 11:00-12:00 Dismantle: 16:00-16:30

CongrEss VEnUE inFormation/ HotEl rEsErVationsHotel Auditórium MadridAvenida de Aragón, 400, 28022 MadridThe hotel is conveniently situated near the Madrid International Airport Barajas and is approximately 16 km (10 miles) from central Madrid.

ispor rates: The discounted room rate for ISPOR congress attendees is r113 for single occupancy and r128 for double occupancy. These rates include applicable taxes and daily complimentary buffet breakfast. Delegate rates are available until the deadline of 6 November 2011 (subject to availability)reservations: Must be made using the Hotel Auditórium online reservation system available at www.ispor.org (Event name: ISPORNOV). Cancellations or changes to reservations without penalty must be made 30 days prior to arrival.

ISPOR 14th AnnuAl EuROPEAn COngRESS

5-8 nOvEmbER 2011 n mAdRId, SPAIn SAtuRdAY, 5 nOvEmbER All dAY COuRSE (9:00-18:00)

introduction to pharmacoeconomicslieven annemans, phd, mman, msc, Ghent University – Brussels University, BelgiumThis course incorporates pharmacoeconomics into study design and data analysis. Participants collect and calculate costs of different alternatives, determine the economic impact of clinical outcomes, and identify, track and assign costs to different types of health care resources used.

SAtuRdAY, 5 nOvEmbER mORnIng COuRSES (9:00-13:00)NEW! introduction to design & analysis of retrospective database studies michael Johnson, phd, College of Pharmacy, University of Houston, USA This course will provide an overview of analytic techniques and specific best practices to improve causal inference in retrospective database studies, including an introductory level discussion of causal graphs, stratification analysis, propensity scoring, instrumental variable and structural modeling techniques.

introduction to patient-reported outcomes assessment: instrument development & evaluationandrew lloyd, dphil; annabel nixon, phd; & sarah acaster, msc, Oxford Outcomes, UKInstrument development and evaluation includes psychometric analyses such as the use of factor analysis and other techniques. This course will cover the recent draft guidance from the FDA as well as existing guidance from the EMEA regarding instrument development.

introduction to modeling uwe siebert, md, mph, msc, scd, University of Health Sciences, Medical Informatics and Technology, Austria, & Harvard Medical School, Boston, MA, USAThis course presents an introductory discussion of pharmacoeconomic modeling techniques such as Monte Carlo analysis, Markov modeling, and probabilistic sensitivity analysis.

discrete event simulation for economic analyses – conceptsJ. Jaime caro, mdcm, fcrpc, facp, McGill University & United BioSource Corporation, USA; Jörgen möller, msc mech eng, United BioSource Corporation, SwedenTopics to be covered are: How does it work, what are the components of a DES, where is it used, for which problems is DES well suited, what are the advantages and disadvantages of DES, PSA as a simple task.

Bayesian methods in economic evaluations – introduction christopher s. hollenbeak, phd, Penn State College of Medicine, USA This course provides an overview of the Bayesian approach and its applications to health economics and outcomes research. It covers basic elements of Bayesian statistics, contrasting briefly with classical (frequentist) statistics and introduces available statistical packages.

statistical methods for pharmacoeconomics & outcomes researchandrew Briggs, phd, University of Glasgow, UK; neil hawkins, phd, msc, University of York, UKAn introduction to statistical methods with an emphasis on the use of techniques commonly employed in pharmacoeconomics and outcomes research is given. Key considerations for planning and analyzing studies and interpreting results will be reviewed. Differences between a classical (frequentist) approach to statistics and a Bayesian view of probability are discussed.

cost-effectiveness analysis alongside clinical trialsscott ramsey, md, phd, Fred Hutchinson Cancer Research Center, USA; sean sullivan, phd, msc, University of Washington, USA; richard Willke, phd, Pfizer, Inc, USA This course will present the design, conduct, and reporting of cost-effectiveness analyses alongside clinical trials. Trial design, selecting data elements, database design and management, analysis, and reporting of results will be presented.

elements of pharmaceutical/Biotech pricing i – introduction Jack m. mycka, Global MME LLC, USA; renato dellamano, phd, MME Europe & ValueVector, Italy This course gives participants a basic understanding of the key terminology and issues involved in pricing decisions. It covers the tools to build and document product value, the role of pharmacoeconomics and the differences in payment systems that help to shape pricing decisions.

SAtuRdAY, 5 nOvEmbER AftERnOOn COuRSES (14:00-18:00)meta-analysis & systematic literature reviewneil hawkins, phd, msc, University of York, UK; olivia Wu, phd, msc, University of Glasgow, UKThis course highlights and expounds upon four key areas: 1) impetus for meta-analysis and systematic reviews; 2) basic steps to perform a quantitative systematic review; 3) statistical methods of combining data; and 4) appraisal and use of meta-analytic reports.

applications in using large european databasesJohn parkinson, phd, GPRD, UK; ron herings, phd, pharmd, Pharmo, The Netherlands; rob thwaites, ma, mcom, United BioSource Corporation, UKThis course evaluates European health care databases, discussing each in-depth with directions on how to access information and how researchers utilize this information. The ISPOR International Digest of Databases - a tool that identifies databases around the world for research purposes - will be discussed.

patient registriesleanne larson, mha, Outcome, USA; michelle Bulliard, rn, Bscn, micr, Outcome, Switzerland; elizabeth hernberg-stahl, msc, Late Phase Solutions Europe AB, SwedenThis course reviews patient registries and their applications in identifying “real world” clinical, safety, and patient-perspective issues. The pros and cons of registry data and how it can support health economics/outcomes research initiatives and decision making are addressed. Registry strategy, design, operations and measures of program success are discussed.

advanced retrospective database analysisWilliam h. crown, phd, Optum Insights, USAThis course discusses the ISPOR Checklist for Retrospective Database Studies and selected topics related to estimators and sampling distributions, properties of sampling distributions, and ordinary least squares (OLS) regression.

utility measurements (preference-Based techniques)Jan Busschbach, phd, Erasmus Medical Center & Viersprong Institute for Studies on Personality Disorders, The NetherlandsMethods for measuring preference-based outcomes and important issues are reviewed, such as: potential insensitivity of generic instruments for disease-specific problems, and to what extent adaptation of generic or disease-specific quality of life instruments may offer a solution.

pharmacoeconomic modeling – applicationsmark s. roberts, md, mpp, University of Pittsburgh Graduate School of Public Health, USAStudents will have hands-on experience in constructing a decision analysis tree including Markov models, Monte Carlo simulations, sensitivity analysis, determination of probability values and transition probabilities. This course is a follow-up to “Introduction to Modeling”.

discrete event simulation for economic analyses – applicationsJ. Jaime caro, mdcm, fcrpc, facp, McGill University & United BioSource Corporation, USA; Jörgen möller, msc mech eng, United BioSource Corporation, Sweden Topics to be covered are: Components of a DES; How do you build a model? Modeling of processes and resource use; Modeling of variables and decisions. Simple animation will be demonstrated using ARENA software.

introduction to health technology assessment (hta)uwe siebert, md, mph, msc, scd, University of Health Sciences, Medical Informatics and Technology, Austria, & Harvard Medical School, USAThis course introduces key elements, methods and language of health technology assessment (HTA) and provides an overview of basic HTA disciplines. Using real world examples, the course

reviews the practical steps involved in developing and using HTA reports in different countries and health care systems.

SundAY, 6 nOvEmbER mORnIng COuRSES (8:00-12:00)

Bayesian methods in economic evaluations – advanced Keith r. abrams, phd, University of Leicester, UKThis course covers the differences between Bayesian and classical approaches, and the application of Bayesian analysis to clinical trials and cost-effectiveness analyses.

reimbursement systems in europeJames furniss; sasha richardson, mBa; & timothy fitzgerald, Bridgehead International, UKThis course reviews procedures employed by European health authorities to regulate market access. Faculty describe reimbursement legislation, processes and organizations of various countries and describe the role of the pharmaceutical and/or medical device manufacturer.

risk-sharing/performance-Based arrangementsadrian towse, ma, mphil, Office of Health Economics, UK; lou Garrison, phd; & Josh carlson, phd, University of Washington, USA Theory and practice, including incentives and barriers, of these arrangements are analyzed using examples of performance-based schemes from Europe, the United States, and Australia.

case studies in pharmaceutical/Biotech pricing ii – advancedJack m. mycka, MME LLC, USA; renato dellamano, phd, MME Europe & ValueVector, Italy Case studies analyze new product pricing, focusing on the need to thoroughly evaluate the business environment and the need to integrate pricing, reimbursement and pharmacoeconomics strategies with clinical development and marketing strategies.

transferability of cost-effectiveness data between countriesJl (hans) severens, phd; smaa evers, phd ll.m; & ma Joore, phd, Maastricht University, The Netherlands This course discusses factors that make economic data more difficult to transfer from one country to another than clinical data, and the evidence on the variability of cost-effectiveness results across countries. We will review the methods that offer a solution and their pros and cons. Finally, we will discuss emerging international guidance for dealing with issues of transferability.

cost estimation and assessing financial (Budget) impact of new health care technologiesJosephine mauskopf, phd, RTI Health Solutions, USA; c. daniel mullins, phd, University of Maryland, USA Learn methods to determine the cost-of-illness of a health condition using a “top-down” or “bottom-up” approach. Learn how to estimate the impact of new health care technologies.

NEW! establishing the content Validity of patient-reported outcome (pro) instruments donald l. patrick, phd, msph, University of Washington; mona l. martin, rn, mpa, Health Research Associates, Inc.; chad Gwaltney, phd, Brown University, USA Requirements for establishing content validity of PRO instruments, definitions of evidence requirements, issues necessitating clarity, and logistical needs for gathering acceptable evidence are covered. Practical exercises are used to establish evidence of content validity for PRO instruments.

NEW! conjoint analysis – theory & methodsa. Brett hauber, phd, RTI Health Solutions, USA; John f. p. Bridges, phd, Johns Hopkins Bloomberg School of Public Health, USA Discuss the conceptual basis for quantifying decision maker preferences for medical interventions and practical design and analytical issues that must be addressed to obtain valid empirical preference estimates.

NEW! network meta-analysis in relative effectiveness research Jeroen p. Jansen, phd, Mapi Values, USA The fundamentals and concepts of network meta-analysis will be presented and proposed. Case studies are implemented with the WinBUGS package. This course requires basic knowledge of meta-analysis and statistics.

– 2 –Full Short course descriptions at www.ispor.org

ISPOR 14th AnnuAl EuROPEAn COngRESS

5-8 nOvEmbER 2011 n mAdRId, SPAIn

– 3 –

SAtuRdAY, 5 nOvEmbER

9:00-18:00 PRE-CONGRESS SHORT COURSES

18:15-19:15 EDUCATIONAL SYMPOSIUM ValuinG innoVation: should innoVation Be considered in pricinG and reimBursement of health care technoloGies?This symposium will discuss ways of defining and measuring innovation and the use of value-based pricing to reflect the value of innovation in pricing and reimbursement decisions. A case study illustrat-ing the estimation of the full life-cycle value of an innovative technology will be presented. (Sponsored by OptumInsight)

19:30-20:30 EDUCATIONAL SYMPOSIUM Value Based pricinG – past, present and the futureAn overview of VBP using examples of health care systems in which it has been implemented will be presented. An explanation of how value assessments have been conducted within the VBP agenda in key markets and the challenges of introducing VBP into a health care system, using the example of the UK, will be provided. This symposium will provide insight into the challenges and identify the differ-ences in the relative importance of VBP elements for different market and therapy areas. (Sponsored by Double Helix)

SundAY, 6 nOvEmbER

8:00-12:00 PRE-CONGRESS SHORT COURSES

12:00-12:30 EXHIBITS & POSTER PRESENTATIONS – SESSION I

12:30-14:15 WELCOME & FIRST PLENARY SESSIONWelcome & presentation of ispor serVice aWards & VALUE IN HEALTH aWard mark J. sculpher, msc, phd, 2011-2012 ISPOR President and Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK

conGress proGram oVerVieWXavier Badia, phd, md, mph, Program Committee Chair

first plenary session: pros and cons of a centraliZed european pricinG & reimBursement aGencyOne of the goals of the European Union (EU), established in 1993, is the integration of processes which are common to all member countries. For example, the European Medicines Agency (EMA) is responsible for the evaluation of medicine applications for European marketing authorization. Under this centralised procedure companies submit a single marketing authorisation application to the Agency. Once granted, marketing authorisation is valid in all 27 EU member countries. Many of the processes for evaluating a new drug, device, or diagnostic for pricing and reimbursement decisions are common to all EU member countries. Should an agency similar in structure to EMA be established with a centralized procedure for pricing and reimbursement? Should this be a decision making agency or only undertake health technology assessment? If the latter, what forms of evaluation should be undertaken? The pros and cons of such an agency will be debated.

moderator: mark J. sculpher, msc, phd, Professor of Health Economics, Centre for Health Econom-ics, University of York, Heslington, York, UKspeakers: hans-Georg eichler, md, msc, Profesor & Senior Medical Officer, European Medicines Agency and CBI Visiting Scholar & Robert E. Wilhelm Fellow, Massachusetts Institute of Technology, London, UK; adrian towse, ma, Director, Office of Health Economics, London, UK

14:45-15:45 ISSUE PANELS – SESSION Iip1: ValuinG diaGnostics: do We need different metrics? moderator: peter J. neumann, scd, Professor & Director, The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA panelists: mark J. sculpher, phd, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK; Ken redekop, phd, Associate Professor, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands; manuel García-Goñi, phd, Assistant Professor, Applied Economics, University of Madrid, Madrid, Spain ip2: Value-Based pricinG: hoW do approaches Vary By health care conteXt? moderator: Bengt Jonsson, phd, Professor of Economics, Stockholm School of Economics, Stockholm, Sweden panelists: isao Kamae, md, drph, Professor, Department of Pharmacoeconomics, Keio University Graduate School of Health Management, Fujisawa, Japan; J-matthias Graf von der schulenburg, phd, Professor of Economics & Director, Institute of Risk and Insurance, Gottfried Wilhelm Leibniz Universität Hannover, Hannover, Germany; michael drummond, mcom, dphil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK ip3: GreenparK collaBoratiVe pilot moderator: sean tunis, md, msc, Founder & Director, Center for Medical Technology Policy, Baltimore, MD, USA panelists: marc Berger, md, Executive Vice President & Senior Scientist, Life Sciences, OptumInsight, New York, NY, USA; hans-Georg eichler, md, msc, Profesor & Senior Medical Officer, European Medicines Agency and CBI Visiting Scholar & Robert E. Wilhelm Fellow, Massachusetts Institute of Technology, London, UK; finn Børlum Kristensen, md, phd, Director of Coordinating Secretariat, European network for Health Technology Assessment (EUnetHTA) and Chairman of the EUnetHTA Executive Committee, Copenhagen, Denmark

ip4: multicriteria decision analysis (mcda): a common road map from druG deVelopment to reGulatory and reimBursement decisions? moderator: ron Goeree, ma, Director, Programs for Assessment of Technology in Health Research Institute, McMaster University, Hamilton, ON, Canada panelists: Bruno flamion, md, phd, Pharmacological and Medical Expert, Federal Agency for Medicines and Health Products, Brussels, Belgium; carole longson, phd, Director, Centre for Health Technology Evaluation, National Institute for Health and Clinical Excellence (NICE), Manchester, UK; mireille Goetghebeur, phd, Vice President, Operations, BioMedCom Consultants Inc., Dorval, QC, Canada ip5: the impact of reGulatory (fda and ema) and eunethta Guidelines on patient-reported outcomes and health-related Quality of life on marKet authorisation and pricinG moderator: Benoit arnould, phd, Director, MAPI Group, MAPI Values, Lyon, France panelists: mira pavlovic, md, Deputy Director, DEMESP, French National Authority for Health (HAS), Saint-Denis la Plaine, France; tara symonds, phd, Senior Director, Outcomes Research, Pfizer Ltd., Sandwich, Kent, UK; paul trueman, ma, EU Development Director, Mapi Values, Bollington, Cheshire, UK

16:00-17:00 WORKSHOPS – SESSION I W1: comparatiVe effectiVeness analyses usinG simulated treatment comparison (stc) discussion leaders: K. Jack ishak, phd, Director, Biostatistics & Senior Research Scientist, United BioSource Corporation, Dorval, QC, Canada; laurent eckert, phd, sanofi-aventis R&D, Massy, France; J. Jaime caro, mdcm, frcpc, facp, Senior Vice President of Health Economics, United BioSource Corporation, Lexington, MA, USA W2: modelinG early pricinG and strateGic assessments of oncoloGy aGents discussion leaders: adam lloyd, mphil, Senior Principal, IMS Health, London, UK; Julie munakata, ms, Principal, HEOR, IMS Consulting Group, Redwood City, CA, USA; thomas tencer, phd, Global Market Access and Health Economics, Eisai, Inc., Woodcliff Lake, NJ, USA W3: dealinG With eXternalities Within the conteXt of health technoloGy assessments discussion leaders: aline Gauthier, msc, Director, Health Economics and Outcomes Research, Amaris Consulting UK, London, UK; lieven annemans, phd, Professor, Centre for Health Economics Research and Health Economist, I-CHER, University of Ghent, Ghent, BelgiumW4: moVinG toWards Value Based health care in different constituencies: a presentation on Behalf of the ispor Value Based health care special interest Group discussion leaders: rachael fleurence, phd, Director, Oxford Outcomes, Bethesda, MD, USA; edward Kim, md, mBa, Executive Director, Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; eldon spackman, phd, Research Fellow, Center for Health Economics, University of York, Heslington, York, UK; huseyin naci, mhs, PhD Candidate, London School of Economics, London, UK W5: multiple criteria decision analysis for health technoloGy assessment discussion leaders: praveen thokala, phd, Research Associate, University of Sheffield, Sheffield, UK; alejandra dueñas, phd, Associate Professor of Operations Management, Management Department, IÉSEG School of Management - Lille-Paris, Paris, France; nancy J. devlin, phd, Director of Research, Office of Health Economics, London, UKW6: miXinG modes of patient-reported outcomes data collection in clinical trials: ispor pro Good research practice tasK force report recommendations discussion leaders: stephen Joel coons, phd, Executive Director, Patient-Reported Outcome (PRO) Consortium, Critical Path Institute, Tucson, AZ, USA; damian mcentegart, msc, Senior Director, Statistics & Product Support Services, Perceptive Informatics, Nottingham, UK; sonya eremenco, ma, e-PRO Manager, United BioSource Corporation, Bethesda, MD, USA; Jean paty, phd, Founder & Senior Vice President, Scientific, Quality & Regulatory Affairs, Invivodata, Inc., Pittsburgh, PA, USA W7: prospectiVe oBserVational studies for neWly launched druGs to assess relatiVe effectiVeness discussion leaders: adrian towse, ma, Director, Office of Health Economics, London, UK; sebastian schneeweiss, md, scd, Director of Drug Evaluation and Outcomes Research, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA; mark cziraky, pharmd, Vice President, Research Development and Operations, HealthCore, Inc., Wilmington, DE, USA; Wim Goettsch, phd, Deputy Secretary of the Medicinal Products Reimbursement Committee and European network for Health Technology Assessment (EUnetHTA) Partner, Health Care Insurance Board (CVZ), Diemen, The Netherlands W8: WorKinG With physicians, medical records, and patients to collect oBserVational, real-World data: the Good, the Bad, and the uGly discussion leaders: elisa cascade, mBa, Vice President, MediGuard.org, Rockville, MD, USA; david ford, mBa, frsa, Director, Health Informatics Research Labs, Swansea University, Swansea, UK; melanie Blackwood, msc, EU Head of Late Phase Project Management, Quintiles, Bracknell, Berkshire, UK

17:15-18:15 WORKSHOPS – SESSION II W9: GeneraliZed eVidence synthesis in comparatiVe effectiVeness research: could the eVidence Base Be Broadened in miXed treatment comparisons? discussion leaders: david Vanness, phd, Assistant Professor, Department of Population Health Sciences, University of Wisconsin, Madison, WI, USA; agnes Benedict, msc, ma, Research Scientist, United BioSource Corporation, Budapest, Hungary W10: a reVieW of the technical support documents for the application of nice methods Guidance on the measurement and Valuation of health discussion leaders: John Brazier, phd, Professor, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK; louise longworth, phd, Reader in Health Economics, Health Economics Research Group, Brunel University, Uxbridge, UK; roberta ara, msc, Research Fellow, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK; andrew J. lloyd, dphil, Director, Oxford Outcomes, Oxford, UK

PROgRAm

ISPOR 14th AnnuAl EuROPEAn COngRESS

5-8 nOvEmbER 2011 n mAdRId, SPAIn

W11: proBlematic sensitiVity analysis: draWBacKs and a Way forWard discussion leaders: Julie roiz, msc, Senior Specialist, Health Economics, GlaxoSmithKline Biologicals, Wavre, Belgium; Gerhart Knerer, ma, msc, PhD Student, Department of Operational Research, University of Southampton, Southampton, UKW12: Biosimilar access: the future of Value assessment discussion leaders: cyrus a. chowdhury, msc, Vice President, Global Market Access, Insight Strategy Advisors, New York, NY, USA; monica martin de Bustamante, Fellow, Global Market Access, Insight Strategy Advisors, New York, NY, USA; corinna sorenson, mph, mhsa, Research Fellow, European Health Policy, Health & Social Care, London School of Economics and European Health Technology Institute for Socio-Economic Research, London, UK W13: hta in Germany: eVidence reQuirements, the role of Benefit/cost assessment, first eXperiences and challenGes With the German health Bill amnoG discussion leaders: anne Kilburg, msc, Senior Director, Market Access and Outcomes Strategy - Europe, RTI Health Solutions, Manchester, UK; peter Kolominsky-rabas, phd, mBa, Director, Centre for Health Technology Assessment (HTA) and Public Health (IZPH), University of Erlangen-Nurnberg, Erlangen, Germany; Jens Grueger, phd, Vice President & Head, Global Market Access Primary Care, Pfizer Ltd., Tadworth, Surrey, UK; anne heyes, mBa, Head, Market Access and Outcomes Strategy - Europe, RTI Health Solutions, Manchester, UK W14: ValuinG health in economic eValuations; innoVatiVe responses to methodoloGical challenGes discussion leaders: Ben a. Van hout, phd, Professor of Health Economics, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK; paul f.m. Krabbe, phd, Associate Professor, Department of Epidemiology, HTA Unit, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; paul Kind, msc, mphil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK; Brendan mulhern, msc, Researcher, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK W15: does oBserVational research support the Goals of comparatiVe effectiVeness research (cer)? discussion leaders: rachael fleurence, phd, Director, Oxford Outcomes, Bethesda, MD, USA; alex exuzides, phd, Director, Late Phase & Outcomes Research, ICON, San Francisco, CA, USA; hannah patrick, mrcp, mfphm, Consultant Clinical Advisor to the IP Programme, National Institute of Clinical Excellence (NICE), London, UKW16: GettinG non-interVentional studies oVer start-up hurdles in europe: staKeholder challenGes & perspectiVes discussion leaders: louise parmenter, phd, Senior Director, Late Phase Strategy and Planning, Quintiles, Inc., Bracknell, Berkshire, UK; herman pieterse, phd, Professor, Clinical Pharmacology, University of Ghent, Heerhugowaard, The Netherlands; Jean-louis merot, md, Senior Director, Late Phase Project Management, Quintiles, Levallois-Perret, France

18:15-19:15 POSTER AUTHOR DISCUSSION HOUR – SESSION I

18:15-20:00 EXHIBITORS’ RECEPTION & POSTER PRESENTATIONS – SESSION I

mOndAY, 7 nOvEmbER

7:00-8:00 EDUCATIONAL SYMPOSIUM the role of health economics professionals as catalysts of chanGe: driVinG chanGe in product deVelopment to satisfy payer reQuirementsThis symposium will address the need for change in product development to satisfy payer stakeholders and the role of health outcomes and health economics departments in leading this change. (Sponsored by PAREXEL International)

8:00-8:30 EXHIBITS & POSTER PRESENTATIONS – SESSION II

8:30-9:45 WELCOME & SECOND PLENARY SESSION Welcome & presentation of ispor research eXcellence aWard mark J. sculpher, msc, phd, 2011-2012 ISPOR President and Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK

second plenary session: the reality of real World data and its use in health care decisions in europeInitial decisions on reimbursement of a new technology usually include the extent to which it does more good than harm under ideal circumstances [efficacy]. However, the goal is to determine the extent to which a technology does more good than harm under usual circumstances of health care practices [effectiveness]. How is this information on ‘usual circumstance of health care practices’ being collected, analyzed, and reported? Who is responsible for collecting, analyzing and reporting the information? Manufacturers? Government? During this session, the issues of collecting and analyzing real world data in Europe, such as patient registry data, reimbursement data, prospective observational studies, or other health care practice-based information will be presented. The question of who is responsible and the real use of this information in healthcare decision-making will be debated.

moderator: Xavier Badia, phd, md, mph, Global Leader, Observational COE & Senior Principal, Health Economics and Outcomes Research, IMS Health, Barcelona, Spain speakers: patrick Keohane, Global Outcomes, AstraZeneca, Södertälje, Sweden; enrique Bernal-delgado, md phd, Head, Health Services Research and Health Policy Unit (ARiHS), Health Research Institute of Aragón (IIS), Co-Chair, Atlas of Variations in Medical Practice in Spain and Scientific Coordi-nator, ECHO Project, Zaragoza, Spain; leslie levin, md, frcp (lon), frcpc, Head & Senior Medical Advisor, Ontario Ministry of Health and Long-Term Care, Toronto, ON, Canada

9:45-10:15 BREAK, EXHIBITS & POSTER PRESENTATIONS – SESSION II

10:15-11:15 ISSUE PANELS – SESSION II ip6: opportunities and challenGes for comparatiVe effectiVeness praGmatic clinical trials in europe moderator: marc l. Berger, md, Executive Vice President & Senior Scientist, Life Sciences, OptumInsight, New York, NY, USA panelists: sean tunis, md, msc, Founder & Director, Center for Medical Technology Policy, Baltimore, MD, USA; david price, md, Professor & Director, Optimum Patient Care Ltd., Cawston, UK; finn Børlum Kristensen, md, phd, Director of Coordinating Secretariat, European network for Health Technology Assessment (EUnetHTA) and Chairman of the EUnetHTA Executive Committee, Copenhagen, Denmark ip7: personaliZed medicine and companion diaGnostics in oncoloGy: hoW do these neW innoVatiVe technoloGies influence health policy and deriVe Value Without specific desiGns for comparatiVe effectiVeness? moderator: michael drummond, mcom, dphil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK panelists: sean d. sullivan, phd, rph, ms, Professor & Director, Pharmaceutical Outcomes Research and Policy Program, University of Washington School of Pharmacy, Seattle, WA, USA; steve clark, Ba, Vice President, Market Access & Reimbursement, i3 Innovus, Eden Prairie, MN, USA; Josephine sollano, phd, Head of Oncology, Outcomes, Pfizer, New York, NY, USAip8: Value-Based pricinG: What Will it mean in practice? moderator: John Brazier, phd, Professor, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK panelists: Karl claxton, phd, Professor & Senior Research Fellow, Centre for Health Economics, University of York, Heslington, York, UK; Jens Grueger, phd, Vice President & Head, Global Market Access Primary Care, Pfizer Ltd., Tadworth, Surrey, UK; adrian towse, ma, Director, Office of Health Economics, London, UK ip9: hta of medical deVices in europe: cooperation BetWeen eValuation aGencies and implications for industry moderator: Geoffrey Wilson, dphil, msc, Head of Health Economics & Reimbursement, EMEA, GE Healthcare, Chalfont-St-Giles, Bucks, UK panelists: Ken redekop, phd, Associate Professor, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands; antonio sarría-santamera, md, phd, Director, Department of Social Medicine, Agency for Health Technology Assessment, Madrid, Spain; francois meyer, md, Director HTA Division, Department of Medical, Economic and Public Health, French National Authority for Health (HAS), Paris, France ip10: hoW Will innoVator technoloGies fare in an increasinGly restrictiVe GloBal reimBursement enVironment: lessons from comparison of cell and Gene therapies to conVentional Biopharmaceuticals moderator: eric c. faulkner, mph, Senior Director, Market Access and Outcomes Strategy, RTI Health Solutions, Research Triangle Park, NC, USA panelists: daryl s. spinner, phd, mBa, Senior Associate, Market Access and Outcomes Strategy, RTI Health Solutions, Research Triangle Park, NC, USA; Koenraad Blot, md, Managing Director, Xintera Consulting, Leuven, Belgium; Katherine payne, phd, Professor, Health Sciences-Economics, University of Manchester, Manchester, UK

11:30-12:30 RESEARCH PODIUM PRESENTATIONS – SESSION I

ASSESSING EFFECT OF MEDICATION ADHERENCE AND PERSISTENCE ON COST-EFFECTIVENESSad1: compliance measurement usinG administratiVe data from German sicKness fundsfrey s, Stargardt T, University of Hamburg, Hamburg, Germanyad2: cost-conseQuence analysis of sWitchinG from an oral antipsychotic to lonG actinG inJectaBle risperidone amonG patients With schiZophreniadegli esposti l, Sangiorgi D, Buda S, CliCon Srl, Ravenna, Italyad3: assessinG the compliance and persistence of allerGen immunotherapy in allerGic rhinitis usinG a retrospectiVe pharmacy dataBase from the netherlandsKiel ma1, Gerth van Wijk R2, Röder E2, Al MJ1, Hop WC2, Rutten-van Mölken MP1, 1Erasmus University, Rotterdam, The Netherlands, 2Erasmus Medical Center, Rotterdam, The Netherlandsad4: predictors and outcomes of patients With acute coronary syndrome Who receiVe optimal therapy: results from the antiplatelet treatment oBserVational reGistries (aptor i and ii)Zeymer u1, Berkenboom G2, Coufal Z3, Belger M4, Tomlin ME5, Sartral M6, Norrbacka K7, Fakhouri W4, Bakhai A8, 1Herzzentrum Ludwigshafen, Ludwigshafen, Germany, 2ULB Erasme University Hospital, Brussels, Belgium, 3Bata’s Regional Hospital, Zlin, Czech Republic, 4Eli Lilly and Company, Windlesham, Surrey, UK, 5Eli Lilly and Company, Indianapolis, IN, USA, 6Eli Lilly and Company, Suresnes, France, 7Eli Lilly and Company, Vantaa, Finland, 8Barnet General Hospital, Barnet, UK

ALTERNATIVE VIEWS IN CANCER OUTCOMES RESEARCHcn1: mean Versus median oVerall surViVal (os) for descriBinG Value of neW cancer therapies: a case studydavies a1, Briggs A1, Wagner S2, Kotapati S3, Schneider J4, Ebeid O4, Levy AR5, 1Oxford Outcomes Ltd., Oxford, UK, 2Bristol-Myers Squibb Company, Washington Crossing, PA, USA, 3Bristol-Myers Squibb Pharmaceuticals, Wallingford, CT, USA, 4Oxford Outcomes Ltd., Morristown, NJ, USA, 5Oxford Outcomes Ltd., Vancouver, BC, Canadacn2: measurinG puBlic preferences for colorectal cancer screeninG usinG neW Genome-Based nanotechnoloGiesFermont JM, Groothuis-Oudshoorn K, iJzerman mJ, University of Twente, Enschede, The Netherlandscn3: Validation study of the Baseline Quality of life as a proGnostic indicator of surViVal: a pooled analysis of indiVidual patient data from ncic clinical trialsediebah de1, Quinten C2, Coens C1, Zikos E1, Ringash J3, Gotay C4, Flechtner HH5, Osoba D6, King M7, Cleeland C8, Greimel E9, Reeve BB10, Taphoorn M11, Schmucker-Von Koch J12, Weis J13, Bottomley

PROgRAm COntInuEd...

– 4 –

PROgRAm COntInuEd...A1, 1European Organisation for Research and Treatment of Cancer Head Quarters, Bruxelles, Belgium, 2European Center for Disease Prevention and Control, Surveillance and Response Support Epidemiological Methods Unit, Stockholm, Sweden, 3The Princess Margaret Hospital, Toronto, QC, Canada, 4University of British Columbia, Vancouver, BC, Canada, 5Otto-von-Guericke University Magdeburg, Magdeburg, Germany, 6Quality of Life Consulting, West Vancouver, BC, Canada, 7University of Sydney, Sydney, Australia, 8University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA, 9Medical University of Graz, Graz, Austria, 10University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 11VU University Medical Center, Department of Neurology, The Hague, The Netherlands, 12University of Regensburg, Regensburg, Germany, 13University of Freiburg, Freiburg, Germanycn4: heteroGeneity in predictinG the future impact of technoloGies to control hepatocellular carcinoma (hcc): a comparison of staKeholder VieWs from europe and asia Bridges Jf1, Gallego G1, Joy SM1, Blauvelt BM2, 1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 2University of Massachusetts, Hadley, MA, USA

NEW APPROACHES FOR EFFECTIVE USE OF DATAda1: artificial neural netWorK meta-models in cost-effectiVeness analysis of intensiVe Blood-Glucose control: a case study applied to the uK prospectiVe diaBetes study (uKpds) indiVidual patient outcome simulation modelalam m1, Briggs A2, 1University of Glamorgan, Pontypridd, UK, 2Glasgow University, Glasgow, UKda2: a choice that matters: comparinG methods of data synthesis in cost-effectiVeness modellinGVemer p, Al M, Oppe M, Rutten-Van Mölken M, iMTA, Erasmus University, Rotterdam, The Netherlandsda3: the poWer of assumptionsVan hout Ba, Stevens JW, University of Sheffield, Sheffield, UKda4: findinG treatment effects Within suBGroups When usinG the propensity score to control for selection Bias: a monte carlo simulation studyvan eeren h1, Spreeuwenberg MD2, van Manen JG3, de Rooij M4, Stijnen T5, Busschbach J1, 1Erasmus University Medical Center, Rotterdam, The Netherlands, 2Maastricht University, Maastricht, The Netherlands, 3Viersprong Institute for Studies on Personality Disorders, Halsteren, The Netherlands, 4Methodology and Statistics Unit, FSW, Leiden University, Leiden, The Netherlands, 5Department of Medical Statistics & Bioinformatics, Leiden University Medical Center, Leiden, The Netherlands

ESTIMATION OF PRODUCTIVITY COSTpc1: productiVity costs in mood disorders – do the methodoloGical challenGes Justify the preclusion of productiVity costs from economic eValuations?lensberg B1, Drummond M2, Danchenko N3, Despiégel N4, François C3, 1OptumInsight, Uxbridge, UK, 2University of York, Heslington, York, UK, 3Lundbeck SAS, Issy-les-Moulineaux , France, 4OptumInsight, Nanterre, Francepc2: estimation of productiVity costs usinG the friction cost method: neW eVidence usinG national dataerdogan-Ciftci E, Koopmanschap ma, Erasmus University Rotterdam, Rotterdam, The Netherlandspc3: Breast and prostate cancer productiVity costs: a comparison of the human capital approach and friction cost approachhanly p, Timmons A, Walsh P, Sharp L, National Cancer Registry Ireland, Cork, Irelandpc4: health serVices utiliZation, WorK aBsenteeism and costs of pandemic influenZa a (h1n1)Garin o1, Galante M1, Sicuri E1, Cots F2, Garcia-Altés A3, Ferrer M4, Nebot M1, Dominguez À1, Alonso J4, 1CIBERESP, Barcelona, Spain, 2Parc de Salut Mar, Barcelona, Spain, 3Catalan Agency for Health Information, Assessment and Quality (CAHIAQ), Barcelona, Spain, 4IMIM-Hospital del Mar, Barcelona, Spain

DIFFERENCES AND OPPORTUNITIES IN PRICING AND MARKET ACCESSpr1: Key marKet access driVers for a successful health technoloGy appraisal outcome – the case of rheumatoid arthritis ackermann J1, Urbinati D2, Strandberg-Larsen M3, Toumi M4, 1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, Luxembourg, Luxembourg, 3Novo Nordisk A/S, Søborg, Denmark, 4University Claude Bernard Lyon 1, Lyon, Francepr2: Value-Based pricinG in the uK: deVelopinG an eValuation frameWorK for Burden of illness easley c1, Tang J2, 1Pope Woodhead & Associates, St Ives, UK, 2Cambridge University, Cambridge, UKpr3: industry preparedness aGainst German reforms Devienne E1, White R2, mukku s2, 1University of Cambridge, Cambridge, UK, 2Double Helix Consulting Group, London, UKpr4: analysis of price leVels of prescription druGs and determinants of inter-national price differences BetWeen the united states and selected european countries Kanavos p, Vandoros S, Ferrario A, London School of Economics and Political Science, London, UK

12:30-14:00 LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS – SESSION II

12:45-13:45 EDUCATIONAL SYMPOSIUM Beyond real-World eVidenceThe current focus of many pharmaceutical organizations is the use of real-world evidence (RWE) in product research and development decisions. However, the field of RWE is by no means clear. Many methodological and perhaps even more fundamental philosophical questions will need to be answered. This symposium will explore the methodological and fundamental philosophical questions relating to the use of RWE and identify future directions beyond RWE. (Sponsored by IMS Consulting Group)

14:00-15:00 WORKSHOPS – SESSION IIIW17: desiGninG Better comparatiVe effectiVeness research discussion leaders: penny mohr, ma, Vice President, Program Development, Center for Medical Technology Policy, Baltimore, MD, USA; richard Gliklich, md, President & CEO, Outcome, Cambridge, MA, USA; robert W. dubois, md, phd, Chief Science Officer, National Pharmaceutical Council, Washington, DC, USA W18: productiVity Gains - underValued and of increasinG importance in an era of shrinKinG numBers of WorKinG-aGed adults? discussion leaders: m.J. postma, phd, Professor, Department of Pharmacy, University of Groningen, Groningen, The Netherlands; mark connolly, phd, Managing Director, Global Market Access Solutions,

St Prex, Switzerland; olivier ethgen, msc, phd, Associate Professor of Health Economics, Department of Public Health Sciences, University of Liege, Liege, Belgium W19: reWardinG innoVation: one step forWard, tWo steps BacK? discussion leaders: alistair mcguire, phd, Head of Social Policy, LSE Health and Social Care, London, UK; michael drummond, mcom, dphil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK; Benedikte lensberg, msc, Project Leader, OptumInsight, Uxbridge, UK; monique martin, msc, mBa, Vice President, UK & French HEOR Operations, OptumInsight, Uxbridge, UK W20: What can patient preference studies tell us aBout patient adherence? a noVel insiGht into an old proBlem discussion leaders: andrew J. lloyd, dphil, Director, Oxford Outcomes, Oxford, UK; a. Brett hauber, phd, Senior Economist and Vice President, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA; John f.p. Bridges, phd, Assistant Professor, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA W21: linKinG eXistinG dataBases – poisoned chalice or holy Grail? discussion leaders: alison Bourke, msc, mrpharms, Managing Director, UK, Cegedim Strategic Data Medical Research Ltd., London, UK; ron m.c. herings, phd, Director, PHARMO Institute, Utrecht, The Netherlands; daniel huse, ma, Vice President, Thomson Reuters, Cambridge, MA, USA; robert J. locasale, phd, ms, Senior Epidemiologist, Epidemiology, Merck, North Wales, PA, USA

15:00-15:15 BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS – SESSION II

15:15-16:15 RESEARCH PODIUM PRESENTATIONS – SESSION II

HEALTH CARE DECISION-MAKER’S CASE STUDIEScase1: therapeutic eQuiValence as a means of improVinG the efficiency in the use of BioloGical aGents in rheumatoid arthritisBautista J1, Garcia Lopez A1, Flores S2, 1Hospital Virgen del Rocio, Sevilla, Spain, 2Agencia de Evaluacion de Tecnologias Sanitarias de Andalucia, Sevilla, Spaincase2: main concerns aBout Bias suBmitted By staKeholders supportinG the introduction of neW druGs into the formulary of the Veneto reGionVisentin E1, alberti c1, Maran PR1, Aiello A2, Magrì MR1, Miggiano C1, Scroccaro G1, 1Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy, 2PBE Consulting, Verona, Italycase3: estaBlishinG a national proGram for puBlic initiation and financinG of research – the case of norWayringard Å, Wang H, Høymork SC, Norwegian Knowledge Centre for the Health Services, Oslo, Norwaycase4: implementation of an online druG monitorinG and safety reGistry for children prescriBed antipsychoticsWegner se1, Trygstad T2, Wegner LM3, McKee J2, Sheitman B3, 1AccessCare, Morrisville, NC, USA, 2North Carolina Community Care Networks, Inc., Raleigh, NC, USA, 3University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

MIXED TREATMENT COMPARISONS MATUREmt1: impact of the choice of prior distriBution on relatiVe effect siZes usinG Bayesian netWorK meta-analysisGoring s1, Ghement I2, Kalsekar A3, L’Italien G4, Levy A5, 1Oxford Outcomes, Vancouver, BC, Canada, 2Ghement Statistical Consulting, Richmond, BC, Canada, 3Bristol-Myers Squibb, Princeton, NJ, USA, 4Bristol-Myers Squibb and Yale University School of Medicine, Wallingford, CT, USA, 5Dalhousie University, Halifax, NS, Canadamt2: the use of continuous data Versus cateGorical data in mtc: the case of haQ multiplier in rheumatoid arthritisschmitz s1, Adams RC2, Walsh C1, Barry M2, 1Trinity College Dublin, Dublin, Ireland, 2National Centre for Pharmacoeconomics, Dublin, Irelandmt3: a Bayesian approach to model selection procedures Within miXed treatment comparison frameWorKosiewalski K, Szmurlo D, HTA Consulting, Krakow, Polandmt4: miXed treatment comparisons usinG aGGreGate and indiVidual-participant leVel data: an efficient use of eVidence for cost-effectiVeness modellinGsaramago p1, Sutton AJ2, Cooper NJ2, Manca A1, 1University of York, Heslington, York, UK, 2University of Leicester, Leicester, Leicestshire, UK

DECISIONS AND THE IMPACT OF NICE IN THE UKni1: the uK nice sinGle technoloGy appraisal process: a QualitatiVe study Based on manufacturers’ suBmissions Kaltenthaler e, University of Sheffield, Sheffield, UKni2: the impact of nice Guidance on the diffusion of medical deVicescabo r1, Sorenson C2, Lynch P3, Eggington S3, 1GE Healthcare, Bucks, UK, 2London School of Economics and European Health Technology Institute for Socio-Economic Research, London, UK, 3Medtronic, Tolochenaz, Switzerlandni3: economic eValuation in niche marKets: the role of the uK’s adVisory Group for national specialised serVices for rare diseases and disordersKhan n1, Kiss N1, Pang F2, 1Oxford Outcomes Ltd., Morristown, NJ, USA, 2Shire Human Genetic Therapies, Inc, Basingstoke, UKni4: the association BetWeen financial impact and the liKelihood of recommendation of medicines for use in enGland and Walesmauskopf Ja1, Chirila‎ C1, Birt J2, Boye KS2, Bowman L2, Grainge‎r D2, 1RTI Health Solutions, Research Triangle Park, NC, USA, 2Eli Lilly and Company, Indianapolis, IN, USA

MERGING PRO AND UTILITY ASSESSMENTut1: comBininG dce and tto into a sinGle Value functionVan hout Ba1, Oppe M2, 1University of Sheffield, Sheffield, UK, 2iMTA, Rotterdam, The Netherlandsut2: update of the patient-reported outcome and Quality of life instruments dataBase (proQolid) usinG the fda Guidance on pro measurescaron m, Perrier LL, Vaissier V, Savre I, Acquadro C, MAPI Research Trust, Lyon, Franceut3: the Validity of the eQ-5d, sf-6d, sf-36 and sf-12 in mental health conditions. a systematic reVieWpapaioannou d, Peasgood T, Brazier J, Parry G, University of Sheffield, Sheffield, UK

– 5 –

PROgRAm COntInuEd...ut4: comparison of the performance of eQ-5d and sf-6d in patients With chronic pain –results from 3 randomiZed controlled trialsobradovic m, Lal A, Liedgens H, Grünenthal GmbH, Aachen, Germany

ADDED VALUE OF VALUE OF INFORMATIONVi1: determininG the impact of modelinG additional sources of uncertainty in Value of information analysiscorro ramos i, Rutten-van Mölken MP, Al MJ, Erasmus University Rotterdam, Rotterdam, The NetherlandsVi2: a noVel approach to analysinG Value driVer importance across multiple tarGet product profilesWild l, Mukku SR, Double Helix Consulting Group, London, UKVi3: seQuential treatment of follicular non-hodGKin lymphoma: cost-effectiVeness and Value of informationsoini eJ1, Martikainen JA1, Vihervaara V2, Mustonen K2, Nousiainen T3, 1ESiOR Ltd, Kuopio, Finland, 2Roche Oy, Espoo, Finland, 3Department of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, FinlandVi4: the Value of information of a multicentre randomised controlled trial of intraVenous immunoGloBulin for sepsis (seVere sepsis and septic shocK)soares mo, University of York, Heslington, York, UK

16:30-17:30 RESEARCH PODIUM PRESENTATIONS – SESSION III

TAKING HETEROGENEITY INTO ACCOUNThG1: applyinG frailty model in lonGitudinal surViVals of chronic diseasesli y, Holtzer-Goor K, Uyl-de Groot C, Al M, iMTA, Erasmus University Rotterdam, Rotterdam, The NetherlandshG2: characteriZinG the indiVidual course of health-related Quality of life after suBarachnoid hemorrhaGeWinter y1, Klotsche J2, Ringel F3, Spottke A4, Gharevi N4, Klockgether T4, Schramm J4, Urbach H4, Wittchen HU2, Rehm J2, Meyer B3, Dodel R1, 1Philipps-University, Marburg, Germany, 2Technical University Dresden, Dresden, Germany, 3Klinikum Rechts der Isar, Technical University, Munich, Germany, 4University of Bonn, Bonn, GermanyhG3: cost comparisons and methodoloGical heteroGeneity in cost-of-illness studies: the eXample of colorectal cancerHanly P1, o’ceilleachair a1, Skally M1, O’Neill C2, Sharp L1, 1National Cancer Registry, Cork, Ireland, 2National University of Ireland Galway, Galway, IrelandhG4: the Value of heteroGeneity for cost-effectiVeness suBGroup analysis: theoretical frameWorK and application espinoza m1, Manca A2, Claxton K3, Sculpher MJ4, 1University of York, Heslington, York, UK

REIMBURSEMENT DECISIONS BASED ON HTA ARGUMENTSht1: effectiVeness, efficiency and BudGet impact affect the BelGian druG reimBursement decision (drd)Bormans V, Van Wilder P, SMART&BI, Zaventem, Belgiumht2: Value-Based pricinG: one threshold too far for the uKroberts G, Double Helix Consulting Group, London, UKht3: understandinG the compleXity of hta netWorKsandreykiv m1, Van Engen A1, Wiebinga C1, Zorzi O1, Mark R2, 1Quintiles, Hoofddorp, The Netherlands, 2Ni3 AG, Zürich, Switzerlandht4: What determines the recommendations issued By polish health technoloGy aGency (ahtapol)?niewada m, Polkowska MA, Jakubczyk M, Golicki D, HealthQuest, Warsaw, Poland

CROSSWALKS BETWEEN QALY INSTRUMENTS AND PROSma1: mappinG the eQ-5d indeX from i-Qol in idiopathic and neuroGenic oaB patients: results from a cross-sectional study in the united states and four european countriesKay s1, Tolley K2, Globe D3, Piercy J4, Anderson P4, 1Adelphi Real World, Bollington, Cheshire, UK, 2Tolley Health Economics, Buxton, UK, 3Allergan, LLC, Irvine, CA, USA, 4Adelphi Real World, Macclesfield, Cheshire, UKma2: mappinG fact-p to country specific patient health status measured By eQ-5d in metastatic castrate resistant prostate cancer patientsspencer m1, Diels J2, 1Janssen-Cilag UK Limited, High Wycombe, UK, 2Janssen Pharmaceutica, Beerse, Belgiumma3: mappinG the diaBetes health profile (dhp-18) onto the eQ-5d and sf-6d Generic preference Based measures of healthmeadows K1, Mulhern B2, Rowen D2, Brazier J2, 1DHP Research & Consultancy Ltd., London, UK, 2University of Sheffield, Sheffield, UKma4: modellinG eQ-5d health state Values: deVelopinG a limited dependent VariaBle, miXture modelinG approachWailoo aJ, Hernández M, Ara R, University of Sheffield, Sheffield, UK

LOOKING BEYOND EXISTING HORIZONSmo1: methods for eXtrapolatinG surViVal data used in nice technoloGy appraisals: inconsistencies and limitationslatimer n, University of Sheffield, Sheffield, UKmo2: eXtrapolation in oncoloGy modellinG: noVel methods for noVel compoundsannemans l1, Asukai Y2, Barzey V2, Kotapati S3, Lees M4, Van Baardewijk M5, Wang Q4, Batty AJ6, Fisher D6, 1Ghent University, Ghent, Belgium, 2IMS Health, London, UK, 3Bristol-Myers Squibb Pharmaceuticals, Wallingford, CT, USA, 4Bristol-Myers Squibb, Uxbridge, Middlesex, UK, 5Bristol-Myers Squibb, Braine L’Alleud, Belgium, 6BresMed Health Solutions, Sheffield, South Yorkshire, UKmo3: a methodoloGical frameWorK for deVelopinG models of Whole disease areas to inform resource allocation decisions tappenden p, Brennan A, Chilcott J, Squires H, University of Sheffield, Sheffield, UKmo4: outcomes Beyond healthJoore ma1, Dellaert B2, Spijkers L1, Severens JL2, Krabbe P3, Dirksen C1, 1MUMC, Maastricht, The

Netherlands, 2Erasmus University Rotterdam, Rotterdam, The Netherlands, 3RUG, Groningen, The Netherlands

RISK SHARING AND PATIENT ACCESSrs1: literature reVieW on patient access schemes, fleXiBle pricinG schemes and risK sharinG aGreements for medicinespuig-peiró r, Mestre-Ferrandiz J, Sussex J, Towse A, Office of Health Economics, London, UKrs2: cost-effectiVeness of end-of-life, life-eXtendinG interVentions: nice’s cost-effectiVeness threshold eXploredhamerslag l, Haynes S, Kusel J, Costello S, Costello Medical Consulting Ltd., Cambridge, UKrs3: eVidence, process or conteXt? eXamininG the factors that driVe coVeraGe decisions of pharmaceuticals By health technoloGy assessment Bodies in europecerri K, Fernández JL, Knapp M, London School of Economics and Political Science, London, UKrs4: the interim cancer druGs fund: hoW to not spend ≤50 milliontimm B, Brooks-Rooney C, Hamerslag L, Costello S, Costello Medical Consulting, Cambridge, UK

17:30-18:30 POSTER AUTHOR DISCUSSION HOUR – SESSION II

17:30-18:30 ISPOR FORUMthe assessment of medical technoloGies in russia: 15 years of road map deVelopmentThis forum will focus on the development of decision making in Russia’s health care system during the last 15 years. The impact of the application of outcomes research, health care expenditure and the recent federal reforms implemented in the Russian Federation health care system will be discussed. Presented by the ISPOR Russia and Russia Far-East Regional Chapters

17:30-19:30 EXHIBITORS’ WINE & CHEESE RECEPTION & POSTER PRESENTATIONS – SESSION II

20:00-23:00 SOCIAL EVENTAn Elegant Dinner at the Casino de Madrid. Please see ISPOR website for details and registration.

tuESdAY, 8 nOvEmbER

7:00-8:00 EDUCATIONAL SYMPOSIUMthe economics of personalised medicineThe promise of personalised medicine is to improve the quality of health care through the use of genetic information. As a new health care technology, genetic testing is demonstrating its potential to ensure that new and existing medical interventions are used more effectively and more safely. In challenging economic times, however, it is particularly important to quantify the impact of genetic testing on clinical and economic outcomes. The development of personalised medicine will further highlight the need for payers and assessment agencies to make trade-offs that are acceptable to the populations they serve. (Sponsored by UBC)

8:00-8:30 EXHIBITS & POSTER PRESENTATIONS – SESSION III

8:30-9:30 ISPOR FORUMSdeVelopinG Good research practices for performance-Based risK-sharinG aGreements: desiGn, implementation, and eValuation In “pay-for-performance” or “risk-sharing” schemes the product’s performance is tracked in a defined patient population over a specified period of time, and the level of reimbursement is tied by formula to the outcomes achieved. The Good Research Practices Task Force will discuss best research practices to assure a product’s performance in a defined patient population over a specified period of time. Presented by the ISPOR Performance-Based Risk-Sharing Arrangements Good Research Practices Task Force

alternatiVe implications of economic crisis on health care in central and eastern europe: an opportunity to improVe decisions or strenGthen cost-containment measures? In challenging economic times governments tend to implement cost-containment measures and improve the efficiency of public spending. The question for policy-makers is whether the goal is really to improve rational health care decision-making or just to reduce public health care spending. Examples of the implications of economic crisis on health care systems in the Central and Eastern European countries will be provided. Presented by the ISPOR Hungary, Slovakia, Republic of Macedonia, Turkish SCP and Czech Regional Chapters

hta deVelopments in the central and eastern european (cee) reGion: locK, stocK & Barrel in challenGinG times During the last six years, health technology assessment/health economics has been increasingly adopted with rapid gains in its perceived value and importance. This forum will present up-to-date HTA requirements and assess the impact of past, current and future HTA implementation on health care decisions in various countries of the CEE region. Presented by the ISPOR Serbia, Greece, Bosnia-Herzegovina, Israel, Poland Regional Chapters

Good research practices for modelinG ISPOR and SMDM developed a series of reports on good research practices (preferred practices) for conducting modeling studies. These recommendations for preferred practices in modeling and the contentious issues debated in their development will be presented. Presented by the ISPOR Modeling Good Research Practices Task Force

hta as a decision-maKinG instrument in health care: eXperience of russia, uKraine, and BelarusThis forum will discuss developments and results of introducing HTA methods in Russia, Ukraine and Belarus, none of which have a formal HTA agency. IT and web-based tools and programs for optimizing drug consumption and assessing costs will be presented. Presented by ISPOR HTA Russia, Ukraine, and Belarus Regional Chapters

9:30-10:00 BREAK, EXHIBITS & POSTER PRESENTATIONS – SESSION III

– 6 –

10:00-11:00 ISSUE PANELS - SESSION IIIip11: multi-criteria decision analysis: an appropriate frameWorK for decision-maKinG aBout neW medical technoloGies? moderator: nancy J. devlin, phd, Ba, Director of Research, Office of Health Economics, London, UK panelists: mark J. sculpher, phd, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK; stuart peacock, dphil, Associate Professor, University of British Columbia and Co-Director, Canadian Centre for Applied Research in Cancer Control (ARCC), Vancouver, BC, Canada; carole longson, phd, Director, Centre for Health Technology Evaluation, National Institute for Health and Clinical Excellence (NICE), Manchester, UK ip12: can We alleViate current marKet failures from international price referencinG of pharmaceuticals in middle income countries? moderator: lou Garrison, phd, Professor, Pharmaceutical Outcomes Research and Policy Program, University of Washington School of Pharmacy, Seattle, WA, USA panelists: Zoltan Kalo, md, msc, phd, Director, Health Economics Research Centre, Eötvös Loránd University, Budapest, Hungary; iga lipska, md, Former Director, HTA Department, Agency for Health Technology Assessment in Poland (AHTAPol), Warsaw, Poland; Jens Grueger, phd, Vice President & Head, Global Market Access Primary Care, Pfizer Ltd., Tadworth, Surrey, UK ip13: it is alWays too early until it is too late: What can We learn from the pilots of multi-staKeholder consultations in early-staGe druG deVelopment? moderator: peter l. Kolominsky-rabas, md, phd, mBa, Director, Centre for Health Technology Assessment (HTA) and Public Health (IZPH), University of Erlangen-Nuremberg, Erlangen, Germany panelists: ron akehurst, Bsc, Professor of Health Economics & Dean of School of Health & Related Research (ScHARR), University of Sheffield, Sheffield, UK; spiros Vamvakas, md, phd, Professor & Head of Scientific Advice, Human Medicines Special Areas, European Medicines Agency (EMA), London, UK; James s. anderson, phd, European Partnerships Director, Government Affairs, Public Policy and Patient Advocacy, GlaxoSmithKline, Brentford, UK ip14: Value-Based reimBursement for personaliZed medicine: Where do We stand? moderator: eric c. faulkner, mph, Senior Director, Market Access and Outcomes Strategy, RTI Health Solutions, Research Triangle Park, NC, USA panelists: anke-peggy holtorf, phd, mBa, Managing Director, Health Outcomes Strategies, GmbH, Basel, Switzerland; michael longacre, Bs, Director, Global Reimbursement Strategy & Payment Policy, Becton Dickenson, Washington, DC, USA; lieven annemans, phd, Professor, Centre for Health Economics Research and Health Economist, I-CHER, University of Ghent, Ghent, Belgium ip15: analytic hierarchy process and conJoint analysis: tWo approaches to include patients’ preferences for therapeutic pathWays and outcomes into health economic analysis moderator: andreas Gerber, phd, md, Head, Department of Health Economics, Institute of Quality and Efficiency in Health Care (IQWiG), Cologne, Germany panelists: axel mühlbacher, phd, Professor for Health Economics, IGM Institute Health Economics and Health Care Management, Hochschule Neubrandenburg, Neubrandenburg, Germany; maarten ijzer-man, phd, Professor, Department of Health Technology and Services Research, University of Twente, Enschede, The Netherlands

11:00-12:00 POSTER AUTHOR DISCUSSION HOUR – SESSION III

11:30-13:00 LUNCH, EXHIBITS & POSTER PRESENTATIONS – SESSION III

11:45-12:45 EDUCATIONAL SYMPOSIUM industry inVolVement in the hta process: Value or Bias?HTA agencies and HTA stakeholders seem to agree that there is value in stakeholder involvement in the HTA process. However there is disagreement on the degree of stakeholder involvement, particularly the degree of industry involvement. Industry develops the technologies that are being assessed and are in possession of key information and data but does their involvement compromise the independence and therefore the effectiveness of HTA agencies? How should industry involvement be managed to bring greatest value to the HTA process? This symposium will present a discussion on the appropriate degree of industry involvement in the HTA process. (Sponsored by EFPIA)

13:00-14:15 THIRD PLENARY SESSION heteroGeneity in the cost-effectiVeness of medical interVentions: the challenGe of matchinG patients to appropriate care Inevitable variation between patients in the effects of disease and responses to treatment gives rise to heterogeneity in the benefits and costs of interventions. This heterogeneity challenges payers in selecting the most appropriate intervention given patients’ observed characteristics such as medical history and disease characteristics. The need to understand heterogeneity in the costs and benefits of interventions raises important methodological issues: how to make the best use of existing routinely available informa-tion to estimate costs and benefits in sub-groups of patients? how to establish the optimal number of patient sub-groups? the appropriate assessment of the additional information offered by diagnostic tests; and the implications of offering choice to patients and physicians to reveal information on the cost-effectiveness of therapies. During this session, these issues will be presented from the perspective of the researcher, the payer, and a manufacturer of companion diagnostic and drug combinations. moderator: uwe siebert, md, mph, msc, scd, Professor & Chair, Department of Public Health, Medi-cal Decision Making and Health Technology Assessment, UMIT - University of Health Sciences, Medical Informatics and Technology and Oncotyrol Center for Personalized Cancer Medicine, Hall/Innsbruck, Austriaspeakers: Karl c. claxton, msc, dphil, Professor & Senior Research Fellow, Centre for Health Econom-ics, University of York, Heslington, York, UK; andreas Gerber, phd, md, Head, Department of Health Economics, Institute of Quality and Efficiency in Health Care (IQWiG), Cologne, Germany; Greg rossi, phd, Vice President, Global Health Economics and Pricing, Genentech Inc, San Francisco, CA, USA

14:15-14:30 ISPOR RESEARCH PRESENTATION AWARDS

14:30-14:45 BREAK, EXHIBITS & POSTER PRESENTATIONS – SESSION III

14:45-15:45 WORKSHOPS - SESSION IVW22: meta-analyses and indirect comparisons from rcts With small patient numBers discussion leaders: heiner c. Bucher, md, mph, Director, Institute for Clinical Epidemiology &

Biostatistics (CEB), University Clinic Basel, Basel, Switzerland; stefan lange, md, Deputy Director, Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany; uwe siebert, md, mph, msc, scd, Professor and Chair, Department of Public Health, Medical Decision Making and Health Technology Assessment, UMIT - University of Health Sciences, Medical Informatics and Technology and Oncotyrol Center for Personalized Cancer Medicine, Hall/Innsbruck, Austria W23: cohort, multi-cohort or population model? Why, When and hoW? discussion leaders: olivier ethgen, msc, phd, Associate Professor of Health Economics, Department of Public Health Sciences, University of Liege, Liege, Belgium; James o’mahony, ma, PhD Candidate, Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands W24: the appropriateness of the cost per Qaly in the decision-maKinG process discussion leaders: mark nuijten, phd, md, mBa, Consultant, Health Economics, Ars Accessus Medica, Amsterdam (Jisp), The Netherlands; dominique dubois, md, Managing Director, Outcomes Research, Patient Value Solutions, Huldenberg, Belgium; Gerry oster, phd, Vice President, Policy Analysis Inc. (PAI), Brookline, MA, USA W25: productiVity costs in mood disorders – methodoloGical challenGes and potential solutions discussion leaders: michael drummond, mcom, dphil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK; nicolas despiégel, msc, Project Leader, Life Sciences, OptumInsight, Nanterre, France; leona hakkaart, phd, Associate Professor, Erasmus University Rotterdam, Rotterdam, The Netherlands W26: ‘model BustinG’: methods and eXperiences in the critical appraisal of cost-effectiVeness models suBmitted to reimBursement aGencies discussion leaders: eldon spackman, phd, Research Fellow, Center for Health Economics, University of York, Heslington, York, UK; susan Griffin, phd, Research Fellow, Centre for Health Economics, University of York, Heslington, York, UK; rachael fleurence, phd, Director, Oxford Outcomes, Bethesda, MD, USA; edward Kim, md, mBa, Executive Director, Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA W27: hoW much does siZe matter? an eVidence-Based approach to sample-siZe decisions in choice-format conJoint studies discussion leaders: f. reed Johnson, phd, Distinguished Fellow and Principal Economist, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA; a. Brett hauber, phd, Senior Economist and Vice President, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA; deborah marshall, mhsa, phd, Associate Professor, Canada Research Chair, Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada W28: innoVatiVe methods for demonstratinG Value for pharmaceutical products: rethinKinG data analysis With implications for study desiGn and personaliZed medicine discussion leaders: donald e. stull, phd, Director, Retrospective Data Analysis, RTI Health Solutions, Manchester, UK; Katherine houghton, Bsc, Research Health Outcomes Scientist, Retrospective Data Analysis, RTI Health Solutions, Manchester, UK; ari Gnanasakthy, mBa, PRO Expert, Novartis Pharma-ceuticals Corporation, East Hanover, NJ, USA

16:00-17:00 WORKSHOPS - SESSION VW29: deVelopinG risK eQuations to proJect time-to-eVent distriButions in economic models discussion leaders: K. Jack ishak, phd, Director, Biostatistics & Senior Research Scientist, United BioSource Corporation, Dorval, QC, Canada; phil mcewan, phd, Managing Director, HEOR Consulting, Monmouth, Monmouthshire, UK; noemi Kreif, PhD Candidate, Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK W30: noVel methods for characteriZinG uncertainty in economic analysis discussion leaders: Ken o’day, phd, Director, Xcenda, LLC, Palm Harbor, FL, USA; denise Globe, phd, Senior Director, Global Health Outcomes Strategy and Research, Allergan, LLC, Irvine, CA, USA; stephen K. Gruschkus, phd, mph, Assistant Director, Xcenda, LLC, Palm Harbor, FL, USA; Katherine B. Winfree, phd, mph, Research Scientist, Global Health Outcomes, Oncology, Eli Lilly and Company, Indianapolis, IN, USA W31: handlinG uncertainty in a BudGet impact analysis discussion leaders: mark nuijten, phd, md, mBa, Consultant, Health Economics, Ars Accessus Medica, Amsterdam (Jisp), The Netherlands; Ken redekop, phd, Associate Professor, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands; stefan Walzer, phd, ma, Global Health Economics, F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland W32: adaptinG to eVolVinG GloBal eVidence reQuirements in medical deVice deVelopment proGrams discussion leaders: thomas Goss, pharmd, Vice President, Boston Healthcare Associates, Inc., Boston, MA, USA; sheri dodd, msc, Vice President, Reimbursement, Economics and Health Policy, Medtronic Cardiac Rhythm Disease Management, Mounds View, MN, USA; Bernd Brueggenjuergen, md, mph, Managing Director, Alpha Care, GmbH, Celle, Germany W33: oVercominG the compleXity of an increasinGly fraGmented reGional and local marKet access reQuirement discussion leaders: mondher toumi, md, phd, Professor, Market Acess, University Claude Bernard Lyon 1, Lyon, France; claudio Jommi, Associate Professor, Università del Piemonte Orientale and Pharmaceutical Observatory, Cergas, University of Bocconi, Milano, Italy; antoni Gilabert perramon, phd, Managing Director of Pharmaceutical Care and Complementary Benefits, Catalan Health Service, Department of Health and Social Security, Government of Catalonia, Barcelona, SpainW34: BridGinG the Gap in data collection BetWeen resource use and patient-reported outcomes discussion leaders: radek Wasiak, phd, EU Director and Research Scientist, Economic Analysis & Solutions, United BioSource Corporation, London, UK; Betina t. Blak, phd, msc, Health Economist, UK, Cegedim Strategic Data Medical Research Ltd., London, UK; tara symonds, phd, Senior Director, Outcomes Research, Pfizer Ltd., Sandwich, Kent, UK; rob thwaites, ma, Vice President, United BioSource Corporation, London, UKW35: desiGninG and implementinG effectiVe rare disease reGistries discussion leaders: leanne larson, mha, Vice President, Outcome, Cambridge, MA, USA; michelle Bulliard, rn, Director Clinical Operations, Outcome, St-Prex, Switzerland

– 7 –

name deGrees

position orGaniZation

mailinG address

city state Zip country

telephone faX email

memBer id#

ISPOR ShORt COuRSE REgIStRAtIOn ISPOR COngRESS REgIStRAtIOn

Exchange rate as of July 2011 (1.43). The shaded boxes should be used as a reference. All credit card payments to ISPOR are charged in US $ at the exchange rate prevailing at the time of the transaction. Due to this exchange, credit card statements may vary slightly.

QTY FEE TOTAL

short course all day registration

short course half day registration

ispor social event

continuing education accreditation

congress registration

ToTAL REGISTRATIoN FEE:

PAYmEnt InfORmAtIOnPlease enclose a check payable in US dollars or Euros j to: International Society for Pharmacoeconomics and Outcomes Research or ISPOR and send to the ISPOR address given

below or charge to: q VISA q MasterCard q American Express Account Number: __________________________________________ Expiration Date: _______________

Name: _______________________________________________________________________ Authorized Signature: ________________________________________

mail details: If not paying by credit card online, send registration form and payment to: International Society for Pharmacoeconomics and Outcomes Research 3100 Princeton Pike, Building 3 Suite E, Lawrenceville, New Jersey 08648, USA Tel: 1-609-219-0773 Fax: 1-609-219-0774 E-Mail: info@ispor.org Internet: www.ispor.org

payment details: Payment may be made by check, travelers check, bank transfer (there is a USD $40 charge) or credit card. VISA, MasterCard, or American Express will be charged in US dollars. Signature, account number and expiration date

must be included. Non-US checks written in US$ on banks with a US counterpart are at no charge. For Non-US checks written in US$ on banks with NO US counterpart there is USD $25 charge. Phone charges will NOT be accepted.

If payment is being made by your company, please make sure your name is indicated on the check stub or correspondence. For bank transfers, please designate the registration name and/or registration number.

memBership details: If ISPOR cannot verify your current membership, you will be charged the non-member registration rate. The Non-Member rate includes an annual ISPOR member-

ship ($140/$35 Students) , which includes a one year online subscription to Value in Health – The Journal of the International Society for Pharmacoeconomics and Outcomes Research.

* The Non-Member rate includes an annual ISPOR membership ($140/$35 Students).

** one day registration details: One day registration does not include ISPOR membership benefits and cannot be combined.

cancellation details: Cancellation fee before 20 September 2011 is US $145. No refunds given after 20 September 2011.

Online registration available at: www.ispor.org

HALF DAY SHORT COURSE FEES Registration Before 20 September: REGULAR: q r150 US$215 / STUDENT: q r75 US$107 Registration After 20 September: REGULAR: q r200 US$286 / STUDENT: q r100 US$143

ALL DAY SHORT COURSE FEESRegistration Before 20 September: REGULAR: q r300 US$429 / STUDENT: q r150 US$215 Registration After 20 September: REGULAR: q r400 US$572 / STUDENT: q r200 US$286

Social Event Fee Subject to Change

REGISTRATION FEES

ISPOR Member Non-Member*StandardRegistration Before 20 September q r500 US$715 q r600 US$855 Registration After 20 September q r600 US$858 q r700 US$998

Clinical Practitioners (Clinical Practice, Hospital)Registration Before 20 September q r350 US$500 q r450 US$640 Registration After 20 September q r450 US$643 q r550 US$783

Full-Time Government and AcademiaRegistration Before 20 September q r250 US$357 q r350 US$497 Registration After 20 September q r350 US$500 q r450 US$640

Full-Time Students (must provide current enrollment documentation)Registration Before 20 September q r100 US$143 q r125 US$178 Registration After 20 September q r150 US$215 q r175 US$250

One Day Registration (per day)** (One Day registrations cannot be combined)

q 6 Nov q 7 Nov q 8 Nov q r300 US$429 q r400 US$572

Continuing Education Accreditation q r65 US$92 q r65 US$92

ISPOR Social Event q r90 US$128 q r90 US$128 Monday 7 November An elegant dinner at the Casino de Madrid. Please see www.ispor.org.

SATURDAY, 5 NOVEMBER 2011 (All DAY COURSE) 9:00-18:00q Introduction to Pharmacoeconomics

SATURDAY, 5 NOVEMBER 2011 (MORNiNg COURSES) 9:00-13:00q NEW! Introduction to Design & Analysis of Retrospective Database Studies q Introduction to Patient-Reported Outcomes Assessment: Instrument Development & Evaluationq Introduction to Modelingq Discrete Event Simulation for Economic Analyses – Conceptsq Bayesian Methods in Economic Evaluations – Introduction q Statistical Methods for Pharmacoeconomics & Outcomes Research q Cost-Effectiveness Analysis alongside Clinical Trials q Elements of Pharmaceutical/Biotech Pricing I – Introduction

SATURDAY, 5 NOVEMBER 2011 (AfTERNOON COURSES) 14:00-18:00q Meta-Analysis & Systematic Literature Reviewq Applications in Using Large European Databases q Patient Registriesq Advanced Retrospective Database Analysis q Utility Measurements (Preference-Based Techniques)q Pharmacoeconomic Modeling – Applications q Discrete Event Simulation for Economic Analyses – Applications q Introduction to Health Technology Assessment (HTA)

SUNDAY, 6 NOVEMBER 2011 (MORNiNg COURSES) 8:00-12:00q Bayesian Methods in Economic Evaluations – Advanced q Reimbursement Systems in Europeq Risk-Sharing/Performance-Based Arrangements for Drugs and Other Medical Productsq Case Studies in Pharmaceutical/Biotech Pricing II – Advancedq Transferability of Cost-Effectiveness Data between Countriesq Cost Estimation and Assessing Financial (Budget) Impact of New Health Care Technologies q NEW! Establishing the Content Validity of Patient-Reported Outcome (PRO) Instruments q NEW! Conjoint Analysis – Theory & Methodsq NEW! Network Meta-Analysis in Relative Effectiveness Research

ISPOR 14th AnnuAl EuROPEAn COngRESS

5-8 nOvEmbER 2011 n mAdRId, SPAIn